Dolutegravir (DTG), an integrase strand transfer inhibitor (INSTI), is currently recommended for treatment initiation in antiretroviral-naı¨ve by most of clinical guidelines. Data from randomized trials demonstrated superiority of DTG over NNRTI and PI/r, supporting its clinical use especially in first-line regimens with high viral load, regardless of which NRTI pair (TDF/FTC or ABC/3TC) was initiated. Aim of this analysis was to describe DTG use in a representative unselected naı¨ve population in Italy and identify its determinants and patterns of prescription.
Prescription pattern and determinants of dolutegravir use in an antiretroviral-naive HIV-infected population in Italy: data from the ICONA Foundation Cohort Study.
G. NunnariMembro del Collaboration Group
;G. F. Pellicanò.Membro del Collaboration Group
2016-01-01
Abstract
Dolutegravir (DTG), an integrase strand transfer inhibitor (INSTI), is currently recommended for treatment initiation in antiretroviral-naı¨ve by most of clinical guidelines. Data from randomized trials demonstrated superiority of DTG over NNRTI and PI/r, supporting its clinical use especially in first-line regimens with high viral load, regardless of which NRTI pair (TDF/FTC or ABC/3TC) was initiated. Aim of this analysis was to describe DTG use in a representative unselected naı¨ve population in Italy and identify its determinants and patterns of prescription.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
